7788-14-9

Usage

Uses

Used in Pharmaceutical Development:
5-Phenyl-1,2,4-Oxadiazol-3-Amine is used as a scaffold in medicinal chemistry for the development of pharmaceutical drugs, leveraging its potential anti-cancer, anti-bacterial, and anti-inflammatory properties. Its unique structure allows for the design of novel therapeutic agents that can target various diseases and conditions.
Used in Organic Synthesis:
In the field of organic synthesis, 5-Phenyl-1,2,4-Oxadiazol-3-Amine serves as a versatile intermediate for the preparation of various other compounds. Its reactivity and functional groups make it a valuable building block for synthesizing a wide range of organic molecules, including pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Medicinal Chemistry Research:
5-Phenyl-1,2,4-Oxadiazol-3-Amine is utilized in medicinal chemistry research to explore its potential as a lead compound for the development of new drugs. Its unique structure and properties make it an attractive candidate for further investigation and optimization to enhance its therapeutic potential.
Used in Drug Design and Optimization:
As a member of the oxadiazole family, 5-Phenyl-1,2,4-Oxadiazol-3-Amine is employed in drug design and optimization processes. Its structural features can be modified to improve the pharmacokinetic and pharmacodynamic properties of drug candidates, leading to the development of more effective and safer therapeutic agents.

Upstream product

• 157117-82-3 N-benzoyl-N'-benzoyloxy-guanidine 
• 102140-71-6 3-(Benzoylamino)-4-methylfurazan 
• 96798-97-9 N-(4-phenyl-1,2,5-oxadiazol-3-yl)benzamide 
• 106124-28-1 (Z)-4-(5-phenyl-[1,2,4]oxadiazol-3-ylamino)-pent-3-en-2-one 
• 17513-09-6 N′-cyanobenzamidine 
• 1670-14-0 benzamidine monohydrochloride 
• 6041-23-2 methyl N-cyanobenzenecarboximidoate 
• 707-07-3 orthobenzoic acid trimethyl ester 
• 3166-00-5 benzoylguanidine 
• 6041-23-2 methyl N-cyanobenzenecarboximidoate 
• 58455-03-1 3-(benzoylamino)-5-methyl-1,2,4-oxadiazole 
• 7746-72-7 N¹-benzoyl-N³-cyanoguanidine 

Downstream Products

• 3166-00-5 benzoylguanidine 
• 1612-76-6 2-amino-5-phenyl-1,3,4-oxadiazole 
• 52854-30-5 2-cyano-3-(5-phenyl-[1,2,4]oxadiazol-3-ylamino)-acrylic acid ethyl ester 
• 108656-02-6 (Z)-1-phenyl-3-(5-phenyl-[1,2,4]oxadiazol-3-ylamino)-but-2-en-1-one 
• 106124-28-1 (Z)-4-(5-phenyl-[1,2,4]oxadiazol-3-ylamino)-pent-3-en-2-one 
• 52854-32-7 4-(5-phenyl-[1,2,4]oxadiazol-3-yl)-3-thio-allophanic acid ethyl ester 
• 31709-26-9 ethyl [5-phenyl-1,2,4-oxadiazol-3-yl]imidoformate 
• 54356-29-5 N-(5-anilino-[1,2,4]thiadiazol-3-yl)-benzamide 
• 28386-96-1 1-phenyl-3-(5-phenyl-[1,2,4]oxadiazol-3-yl)-urea 
• 55730-04-6 3-oxo-3-phenyl-N-(5-phenyl-[1,2,4]oxadiazol-3-yl)-propionamide 
• 54286-76-9 (Z)-3-phenyl-3-(5-phenyl-[1,2,4]oxadiazol-3-ylamino)-acrylic acid ethyl ester 
• 54286-75-8 (Z)-3-(5-phenyl-[1,2,4]oxadiazol-3-ylamino)-but-2-enoic acid ethyl ester 
• 52770-91-9 3-(acetylamino)-5-phenyl-1,2,4-oxadiazole 
• 67560-24-1 4c-(5-phenyl-[1,2,4]oxadiazol-3-ylamino)-but-3-en-2-one 

Relevant academic research and scientific papers

Convergent Synthesis of PI3K Inhibitor GDC-0908 Featuring Palladium-Catalyzed Direct C-H Arylation toward Dihydrobenzothienooxepines

A practical convergent synthesis of PI3K inhibitor GDC-0908 (1) is described. The process features a dihydrobenzothienooxepine formation via palladium-catalyzed intramolecular direct C-H arylation and a Negishi coupling to construct the key C-C bonds. We

HETEROCYCLIC COMPOUNDS AS PESTICIDES

The present application relates to novel heterocyclic compounds, to the use thereof for controlling animal pests including arthropods, insects and nematodes, and to processes and intermediates for preparation of the novel compounds.

Facile synthesis of 3-amino-5-aryl-1,2,4-oxadiazoles: Via PIDA-mediated intramolecular oxidative cyclization

A mild and efficient method for the synthesis of 3-amino-5-aryl-1,2,4-oxadiazole by intramolecular cyclization using PhI(OAc)2 (PIDA) as an oxidant is developed. Various 3-amino-5-aryl-1,2,4-oxadiazoles are prepared in moderate to good yields,

NOVEL THERAPEUTIC COMPOUNDS

Disclosed herein are novel compounds of Formula (I), wherein the variables are defined as herein. The compounds of Formula (I) are useful as kinase inhibitors and as such would be useful in treating certain conditions and diseases, especially inflammatory conditions and diseases as well as proliferative disorders such as cancer.

A generalized synthesis of 3-amino-5-aryl-, 3-amino-5-polyfluorophenyl-, and 3-amino-5-alkyl-1,2,4-oxadiazoles through ring-degenerate rearrangements

A generalized synthesis of 3-amino-5-aryl-, 3-amino-5-polyfluorophenyl- and 3-amino-5-alkyl-1,2,4-oxadiazoles has been developed starting from the 3-amino-5-methyl-1,2,4-oxadiazole as a common synthon. Aroylation or alkanoylation of this aminooxadiazole,

PHOTOCHEMICAL BEHAVIOUR OF 1,2,5-OXADIAZOLES - IRRADIATION OF SOME 3-ACYLAMINO-1,2,5-OXADIAZOLES IN THE PRESENCE OF NUCLEOPHILES

The photochemical behaviour of some 3-acylamino-1,2,5-oxadiazoles (furazans) has been investigated.On irradiation at 254 nm in the presence of nucleophiles (ammonia, primary or secondary amines), the photoreaction produced 3-substituted 1,2,3-oxadiazoles in which the substituent at C(3) arises from the used reagent.Some mechanistic considerations are reported.

Heterocyclic Rearrangements: Rearrangement of N-(1,2,4-Oxadiazol-3-yl)-β-enamino Ketones into Pyrimidine N-Oxides

The behaviour of N-(5-R-1,2,4-oxadiazol-3-yl)-β-enamino ketones towards rearrangement has been investigated.In the presence of anionic reagents in ethanol solution, they rearrange to pyrimidine N-oxides.The synthesis and hydrolytic ring opening of a oxadiazolopyrimidinium system is also reported.